Sun Pharma’s arm launches WINLEVI in Canada

27 Sep 2023 Evaluate

Sun Pharmaceutical Industries’ wholly owned subsidiary -- Sun Pharma Canada has launched WINLEVI (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne in Canada. WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older.

WINLEVI works differently from any other topical acne treatment. Instead of a topical approach to acne treatment that focuses on follicular hyperkeratinization, reducing inflammation or exerting antibacterial effects, WINLEVI is thought to reduce the effects of acne hormones on skin by disrupting the androgen cascade. While the exact way that WINLEVI works is unknown, it aims to inhibit the effects of androgen receptors in cells of the sebaceous glands (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1827.00 -10.30 (-0.56%)
09-Jan-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1827.00
Dr. Reddys Lab 1371.60
Cipla 1491.70
Lupin 2250.40
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.